Testing the circadian gene hypothesis in prostate cancer: A population-based case-control study

Cancer Research

Volumn 69, Issue 24, 2009, Pages 9315-9322

  Zhu, Yong ^a   Stevens, Richard G ^b   Hoffman, Aaron E ^a   FitzGerald, Liesel M ^c   Kwon, Erika M ^d   Ostrander, Elaine A ^d   Davis, Scott ^c   Zheng, Tongzhang ^a   Stanford, Janet L ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEX HORMONE;

ADULT; AGED; ARNTL GENE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; CIRCADIAN GENE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CLOCK GENE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRY1 GENE; CRY2 GENE; CSNK1E GENE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NPAS2 GENE; PER1 GENE; PER2 GENE; PER3 GENE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; CASE-CONTROL STUDIES; CIRCADIAN RHYTHM; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 73649083745     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0648     Document Type: Article

References (44)

1. Stevens RG. Electric power use and breast cancer: a hypothesis. Am J Epidemiol 1987;125:556-61.
2. Stevens RG, Davis S, Thomas DB, Anderson LE, Wilson BW. Electric power, pineal function, and the risk of breast cancer. FASEB J 1992;6:853-60.
3. Straif K, Baan R, Grosse Y, et al. Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol 2007;8:1065-6.
4. Band PR, Le ND, Fang R, et al. Cohort study of Air Canada pilots: mortality, cancer incidence, and leukemia risk. Am J Epidemiol 1996;143:137-43.
5. Irvine D, Davies DM. British Airways flightdeck mortality study, 1950-1992. Aviat Space Environ Med 1999; 70:548-55.
6. Pukkala E, Aspholm R, Auvinen A, et al. Cancer incidence among 10,211 airline pilots: a Nordic study. Aviat Space Environ Med 2003;74:699-706.
7. Kubo T, Ozasa K, Mikami K, et al. Prospective cohort study of the risk of prostate cancer among rotating-shift workers: findings from the Japan collaborative cohort study. Am J Epidemiol 2006;164:549-55.
8. Conlon M, Lightfoot N, Kreiger N. Rotating shift work and risk of prostate cancer. Epidemiology 2007; 18:182-3.
9. Pukkala E, Ojamo M, Rudanko SL, Stevens RG, Verkasalo PK. Does incidence of breast cancer and prostate cancer decrease with increasing degree of visual impairment. Cancer Causes Control 2006;17:573-6.
10. Feychting M, Osterlund B, Ahlbom A. Reduced cancer incidence among the blind. Epidemiology 1998;9: 490-4.
11. Kondratov RV, Gorbacheva VY, Antoch MP. The role of mammalian circadian proteins in normal physiology and genotoxic stress responses. Curr Top Dev Biol 2007; 78:173-216.
12. Fu L, Lee CC. The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer 2003;3:350-61.
13. Zhu Y, Zheng T, Stevens RG, Zhang Y, Boyle P. Does "clock" matter in prostate cancer? Cancer Epidemiol Biomarkers Prev 2006;15:3-5.
14. Stanford JL, Wicklund KG, McKnight B, Daling JR, Brawer MK. Vasectomy and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 1999;8:881-6.
15. Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL. Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol 2008;168:250-60.
16. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies.. Nat Genet 2005;37:1217-23.
17. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5.
18. Core Genotyping Facility, Office of Cancer Genomics, Division of Cancer Epidemiology and Genetics NCI, National Institutes of Health The Cancer Genetic Markers of Susceptibility Project. Vol. 2006. Bethesda (MD).
19. Tobler AR, Short S, Andersen MR, et al. The SNPlex genotyping system: a flexible and scalable platform for SNP genotyping. J Biomol Tech 2005;16: 398-406.
20. De la Vega FM, Lazaruk KD, Rhodes MD, Wenz MH. Assessment of two flexible and compatible SNP geno-typing platforms: TaqMan SNP Genotyping Assays and the SNPlex Genotyping System. Mutat Res 2005;573: 111-35.
21. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89.
22. Zhu Y, Brown HN, Zhang Y, Stevens RG, Zheng T. Period3 structural variation: a circadian biomarker associated with breast cancer in young women. Cancer Epidemiol Biomarkers Prev 2005;14:268-70.
23. Chu LW, Zhu Y, Yu K, et al. Variants in circadian genes and prostate cancer risk: a population-based study in China. Prostate Cancer Prostatic Dis 2008;11:342-8.
24. Hoffman AE, Zheng T, Stevens RG, et al. Clock-cancer connection in non-Hodgkin's lymphoma: a genetic association study and pathway analysis of the circadian gene cryptochrome 2. Cancer Res 2009;69: 3605-13.
25. Storch KF, Lipan O, Leykin I, et al. Extensive and divergent circadian gene expression in liver and heart. Nature 2002;417:78-83.
26. Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 2002;111: 41-50.
27. Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. Control mechanism of the circadian clock for timing of cell division in vivo. Science 2003; 302:255-9.
28. Granda TG, Liu XH, Smaaland R, et al. Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumor. FASEB J 2005;19:304-6.
29. Lee E, Salic A, Kirschner MW. Physiological regulation of â-catenin stability by Tcf3 and CK1å. J Cell Biol 2001;154:983-93.
30. van de Wetering M, de Lau W, Clevers H. WNT signaling and lymphocyte development. Cell 2002;109 Suppl:S13-9.
31. Morin PJ. â-Catenin signaling and cancer. BioEssays 1999;21:1021-30.
32. Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell 2006;22:375-82.
33. Hoffman AE, Zheng T, Ba Y, Zhu Y. The circadian gene NPAS2, a putative tumor suppressor, is involved in DNA damage response. Mol Cancer Res 2008;6: 1461-8.
34. Brown CE, Warren S, Chute RN, Ryan KJ, Todd RB. Hormonally induced tumors of the reproductive system of parabiosed male rats. Cancer Res 1979;39: 3971-6.
35. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88: 1118-26.
36. Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008;100:170-83.
37. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
38. Soronen P, Laiti M, Torn S, et al. Sex steroid hormone metabolism and prostate cancer. J Steroid Biochem Mol Biol 2004;92:281-6.
39. Francavilla A, Eagon PK, DiLeo A, et al. Circadian rhythm of hepatic cytosolic and nuclear estrogen and androgen receptors. Gastroenterology 1986;91:182-8.
40. Plymate SR, Tenover JS, Bremner WJ. Circadian variation in testosterone, sex hormone-binding globulin, and calculated non-sex hormone-binding globulin bound testosterone in healthy young and elderly men. J Androl 1989;10:366-71.
41. Guignard MM, Pesquies PC, Serrurier BD, Merino DB, Reinberg AE. Circadian rhythms in plasma levels of cortisol, dehydroepiandrosterone, δ 4-androstenedione, testosterone and dihydrotestosterone of healthy young men. Acta Endocrinol 1980;94:536-45.
42. Chu LW, Zhu Y, Yu K, et al. Correlation between circadian gene variants and serum levels of sex steroids and insulin-like growth factor-I. Cancer Epidemiol Biomarkers Prev 2008;17:3268-73.
43. Zhu Y, Stevens RG, Leaderer D, et al. Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk. Breast Cancer Res Treat 2008; 107:421-5.
44. Zhu Y, Leaderer D, Guss C, et al. Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin's lymphoma. Int J Cancer 2007; 120:432-5.